A research group at Kyoto University has confirmed that the addition of capecitabine, an anticancer drug, to standard chemotherapy after surgery for breast cancer increases post-treatment survival.
Even if chemotherapy is given before surgery for breast cancer, if the breast cancer lesions that spread to the tissue remain, the progress after the treatment is not good.In this clinical study, 2 Japanese and Korean human epithelial growth factor receptor type 2 (HER910) -negative patients with or without capecitabine added to standard postoperative chemotherapy (capecitabine group) They were randomly divided into groups (control groups), and the disease-free survival time and overall survival time at 5 years after treatment were compared.
As a result of the analysis, the proportion of patients who did not have recurrence or other diseases at 5 years after treatment was 74.1% in the capecitabine group, compared with 67.6% in the control group, and the disease-free survival of the capecitabine group. The duration was found to be longer than the disease-free survival of the control group.The proportion of patients who survived 5 years after treatment was 89.2% in the capecitabine group and 83.6% in the control group, which was significantly superior to the capecitabine group.
The researchers commented that the results of this study are expected to contribute to improving the prognosis of HER2-negative breast cancer patients and to the progress of breast cancer treatment in the future.
Paper information:[New England Journal of Medicine] Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
